FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Type 2 polysaccharide storage myopathy in Quarter Horses is ...
Equine veterinary journal2022; 55(4); 618-631; doi: 10.1111/evj.13876

Type 2 polysaccharide storage myopathy in Quarter Horses is a novel glycogen storage disease causing exertional rhabdomyolysis.

Abstract: Both type 1 (PSSM1) and type 2 polysaccharide storage myopathy (PSSM2) are characterised by aggregates of abnormal polysaccharide in skeletal muscle. Whereas the genetic basis for PSSM1 is known (R309H GYS1), the cause of PSSM2 in Quarter Horses (PSSM2-QH) is unknown and glycogen concentrations not defined. Objective: To characterise the histopathological and biochemical features of PSSM2-QH and determine if an associated monogenic variant exists in genes known to cause glycogenosis. Methods: Retrospective case control. Methods: Sixty-four PSSM2-QH, 30 PSSM1-QH and 185 control-QH were identified from a biopsy repository and clinical data, histopathology scores (0-3), glycogen concentrations and selected glycolytic enzyme activities compared. Coding sequences of 12 genes associated with muscle glycogenoses were identified from whole genome sequences and compared between seven PSSM2-QH and five control-QH. Results: Exertional rhabdomyolysis in PSSM2-QH occurred predominantly in barrel racing and working cow/roping performance types and improved with regular exercise and a low starch/fat-supplemented diet. Histopathological scores, including the amount of amylase-resistant polysaccharide (PSSM2-QH 1.4 ± 0.6, PSSM1-QH 2.1 ± 0.3, control-QH 0 ± 0, p < 0.001), and glycogen concentrations (PSSM2-QH 129 ± 62, PSSM1-QH 175 ± 9, control-QH 80 ± 27 mmol/kg, p < 0.0001) were intermediate in PSSM2-QH with significant differences among groups. In PSSM2-QH, abnormal polysaccharide had a less filamentous ultrastructure than PSSM1-QH and phosphorylase and phosphofructokinase activities were normal. Seventeen of 30 PSSM2-QH with available pedigrees descended from one of three stallions within four generations. Of the 29 predicted high or moderate impact genetic variants identified in candidate genes, none were present in only PSSM2-QH and absent in control-QH. Conclusions: Analyses of PSSM2-QH and PSSM1-QH were performed on shipped samples, controls on frozen samples. Conclusions: PSSM2-QH is a novel glycogen storage disorder that is not the result of a mutation in genes currently known to cause muscle glycogenoses in other species. Unassigned: Ambos os tipos 1 e 2 de miopatia por acúmulo de polissacarídeo (PSSM) são caracterizados por agregados de polissacarídeos anormais no músculo esquelético. Enquanto a base genética do PSSM 1 é conhecida (R309H GYS1), a causa do PSSM2 em cavalos Quarto de Milha (PSSM2-QH) é desconhecida, e a concentração de glicogênio não é definida. Objective: Identificar as características histopatológicas e bioquímicas do PSSM-QH e determinar se há uma variante monogênica em genes conhecidos por causar glicogenose. Unassigned: Caso controlado retrospectivo. Methods: 64 PSSM2-QH, 30 PSSM1-QH e 185 QH controles foram identificados em um arquivo de dados. Informação clínica, achados histológicos (escala 0-3), concentração de glicogênio e atividade enzimática de algumas enzimas glicolíticas foram comparadas. Sequências codificadas de 12 genes associados com glicogenose muscular foram identificados nas sequências genômicas completas, e comparadas entre 7 PSSM2-QH e 5 QH controles. Results: Rabdomiólise por exercício em PSSM2-QH ocorreu predominantemente em cavalos de corrida de tambor e cavalos de team roping/trabalho com gado, e melhorou com exercício regular e uma dieta com baixo amido e alta gordura. A escala histopatológica, incluindo a quantidade de polissacarídeos resistentes à amilase (PSSM2-QH 1.4 ± 0.6, PSSM1-QH 2.1 ± 0.3, controle-QH 0 ± 0, P < 0.001), e concentrações de glicogênio (PSSM2-QH 129 ± 62, PSSM1-QH 175 ± 9, controle-QH 80 ± 27 mmol/kg, P < 0.0001) foram intermediárias em PSSM2-QH com diferença significante entre grupos. Em PSSM2-QH, polissacarídeo anormal teve uma ultraestrutura menos filamentosa do que PSSM1-QH e as atividades de fosforilase e fosfofrutoquinase foram normais. Dezessete dos 30 PSSM2-QH com pedigree disponível descendiam de 1 de 3 garanhões dentro de 4 gerações. Das 29 variações genéticas preditas a terem impacto moderado ou alto como genes candidatos, nenhuma estava presente apenas em PSSM2-QH e ausente no grupo controle-QH. PRINCIPAIS LIMITAÇÕES: As análises feitas nas amostras de PSSM2-QH e PSSM1-QH foram realizadas em amostras enviadas por correio, e as amostras dos animais controles eram amostras congeladas. CONCLUSÕES: PSSM2-QH é uma nova doença por acúmulo de glicogênio que não é o resultado de uma mutação nos genes conhecidos por causarem glicogenose muscular em outras espécies.
© 2022 The Authors. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd.
Get Full Text
Publication Date: 2022-09-14 PubMed ID: 36102343DOI: 10.1111/evj.13876Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates a specific type of muscle disease, called type 2 polysaccharide storage myopathy (PSSM2), in Quarter Horses. It was found that PSSM2 is a new glycogen storage disorder that is not caused by a mutation in standard glycogenosis causing genes and showed distinct features in comparison to type 1 polysaccharide storage myopathy.

Research Methods

  • A case control approach was utilized, involving 64 PSSM2-QH, 30 PSSM1-QH, and 185 control-QH horses.
  • Clinical information, histopathology scores, glycogen concentrations, and particular glycolytic enzyme activities were compared across the groups.
  • The genetic sequences of 12 genes associated with muscle glycogenoses were identified from whole genome sequences and compared between seven PSSM2-QH and five control-QH.

Results

  • Exertional rhabdomyolysis, a condition characterized by muscle breakdown, was primarily observed in PSSM2-QH horses active in barrel racing and working cow/roping performance activities. This condition seemed to improve with regular exercise and a diet low in starch and supplemented with fats.
  • Both PSSM2-QH and PSSM1-QH had higher histological scores and glycogen concentrations than control-QH, indicating the presence of abnormal polysaccharides. The genetic variance of these traits was distinct between PSSM2-QH and PSSM1-QH, indicating distinct genetic factors influencing each.
  • In PSSM2-QH horses, the microscopic structure of abnormal polysaccharide was less thread-like than in PSSM1-QH horses, and activity of the enzymes phosphorylase and phosphofructokinase were normal.

Genetic Connections

  • It was observed that 17 out of 30 PSSM2-QH horses with known pedigrees descended from one of three stallions within four generations. This suggests a potential genetic predisposition for PSSM2-QH.
  • However, out of 29 high or moderate impact genetic variants identified in muscle glycogenosis associated genes, none were exclusive to PSSM2-QH horses.
  • This outcome indicates that PSSM2-QH is likely not a result of a mutation in any of the genes currently known to cause muscle glycogenoses in other species.

Limitations and Conclusion

  • The major limitation of the study was that the samples from PSSM2-QH and PSSM1-QH were shipped in while control samples were frozen. This could potentially bring bias in results.
  • The study concludes that type 2 polysaccharide storage myopathy in Quarter Horses is a new glycogen storage disorder that does not result from a mutation in genes known to cause similar disorders in other species.

Cite This Article

APA
Valberg SJ, Williams ZJ, Finno CJ, Schultz A, Velez-Irizarry D, Henry ML, Gardner K, Petersen JL. (2022). Type 2 polysaccharide storage myopathy in Quarter Horses is a novel glycogen storage disease causing exertional rhabdomyolysis. Equine Vet J, 55(4), 618-631. https://doi.org/10.1111/evj.13876

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 55
Issue: 4
Pages: 618-631

Researcher Affiliations

Valberg, Stephanie J
  • Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Williams, Zoë J
  • Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Finno, Carrie J
  • Department of Population Health and Reproduction, School of Veterinary Medicine, University of California-Davis, Davis, California, USA.
Schultz, Abigail
  • Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Velez-Irizarry, Deborah
  • Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Henry, Marisa L
  • Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Gardner, Keri
  • Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Petersen, Jessica L
  • Department of Animal Science, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.

MeSH Terms

  • Female
  • Cattle
  • Horses
  • Animals
  • Male
  • Retrospective Studies
  • Glycogen Storage Disease / complications
  • Glycogen Storage Disease / genetics
  • Glycogen Storage Disease / veterinary
  • Muscular Diseases / genetics
  • Muscular Diseases / veterinary
  • Muscular Diseases / pathology
  • Rhabdomyolysis / genetics
  • Rhabdomyolysis / veterinary
  • Muscle, Skeletal / pathology
  • Polysaccharides
  • Glycogen
  • Horse Diseases / genetics
  • Horse Diseases / pathology
  • Cattle Diseases / pathology

Grant Funding

  • L40 TR001136 / NCATS NIH HHS
  • L40 TR001136 / NCATS NIH HHS

References

This article includes 40 references
  1. Valberg SJ, Cardinet GH 3rd, Carlson GP, DiMauro S. Polysaccharide storage myopathy associated with recurrent exertional rhabdomyolysis in horses.. Neuromuscul Disord 1992;2:351-9.
  2. Valentine BA, McDonough SP, Chang YF, Vonderchek J. Polysaccharide storage myopathy in Morgan, Arabian, and Standardbred related horses and Welsh-cross ponies.. Vet Pathol 2000;37:193-6.
  3. McCue ME, Valberg SJ, Miller MB, Wade C, DiMauro S, Akman HO. Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis.. Genomics 2008;91:458-66.
  4. McCue ME, Armien AG, Lucio M, Mickelson JR, Valberg SJ. Comparative skeletal muscle histopathologic and ultrastructural features in two forms of polysaccharide storage myopathy in horses.. Vet Pathol 2009;46:1281-91.
  5. Valentine BA, Cooper BJ. Incidence of polysaccharide storage myopathy: necropsy study of 225 horses.. Vet Pathol 2005;42:823-7.
  6. McKenzie EC, Eyrich LV, Payton ME, Valberg SJ. Clinical, histopathological and metabolic responses following exercise in Arabian horses with a history of exertional rhabdomyolysis.. Vet J 2016;216:196-201.
  7. Valberg SJ, McKenzie EC, Eyrich LV, Shivers J, Barnes NE, Finno CJ. Suspected myofibrillar myopathy in Arabian horses with a history of exertional rhabdomyolysis.. Equine Vet J 2016;48:548-56.
  8. Williams ZJ, Bertels M, Valberg SJ. Muscle glycogen concentrations and response to diet and exercise regimes in Warmblood horses with type 2 polysaccharide storage myopathy.. PLoS One 2018;13:e0203467.
  9. Valberg SJ, Nicholson AM, Lewis SS, Reardon RA, Finno CJ. Clinical and histopathological features of myofibrillar myopathy in Warmblood horses.. Equine Vet J 2017;49:739-45.
  10. Pagan JD, Valberg SJ. Feeding performance horses with myopathies.. In: Proceedings of American Association of Equine Practitioners, San Antonio; 2021. p. 66-74.
  11. Valberg SJH, Henry ML, Herrick KL, Velez-Irizarry D, Finno CJ, Petersen JL. Absence of myofibrillar myopathy in Quarter Horses with a histopathological diagnosis of type 2 polysaccharide storage myopathy and lack of association with commercial genetic tests.. Equine Vet J 2022.
    doi: 10.1111/evj.13574google scholar: lookup
  12. Aleman M, Riehl J, Aldridge BM, Lecouteur RA, Stott JL, Pessah IN. Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia.. Muscle Nerve 2004;30:356-65.
  13. Finno CJ, Gianino G, Perumbakkam S, Williams ZJ, Bordbari MH, Gardner KL. A missense mutation in MYH1 is associated with susceptibility to immune-mediated myositis in Quarter Horses.. Skelet Muscle 2018;8:7.
  14. Valberg SJ, Henry ML, Perumbakkam S, Gardner KL, Finno CJ. An E321G MYH1 mutation is strongly associated with nonexertional rhabdomyolysis in Quarter Horses.. J Vet Intern Med 2018;32:1718-25.
  15. Ward TL, Valberg SJ, Adelson DL, Abbey CA, Binns MM, Mickelson JR. Glycogen branching enzyme (GBE1) mutation causing equine glycogen storage disease IV.. Mamm Genome 2004;15:570-7.
  16. Firshman AM, Valberg SJ, Bender JB, Finno CJ. Epidemiologic characteristics and management of polysaccharide storage myopathy in Quarter Horses.. Am J Vet Res 2003;64:1319-27.
  17. Valberg S, Essen-Gustavsson B, Lindholm A, Persson S. Energy metabolism in relation to skeletal muscle fibre properties during treadmill exercise.. Equine Vet J 1985;17:439-44.
  18. Cumming WJK, Fulthorpe J, Hudgson P, Mahon M. Color atlas of muscle pathology.. London, UK: Mosby-Wolfe; 1994.
  19. Cingolani P, Patel VM, Coon M, Nguyen T, Land SJ, Ruden DM. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift.. Front Genet 2012;3:35.
  20. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3.. Fly (Austin) 2012;6:80-92.
  21. Akman HO, Oldfors A, DiMauro S. Glycogen storage diseases of muscle.. In: Darras B, Royden Jones H Jr, Ryan MM, De Vivo DC, editors. Neuromuscular disorders of infancy, childhood and adolescence. 2nd ed. New York: Elsevier; 2015. p. 735-60.
  22. Almodovar-Paya A, Villarreal-Salazar M, de Luna N, Nogales-Gadea G, Real-Martinez A, Andreu AL. Preclinical research in glycogen storage diseases: a comprehensive review of current animal models.. Int J Mol Sci 2020;21(24):9621.
  23. Ellingwood SS, Cheng A. Biochemical and clinical aspects of glycogen storage diseases.. J Endocrinol 2018;238:R131-41.
  24. Hedberg-Oldfors C, Oldfors A. Polyglucosan storage myopathies.. Mol Aspects Med 2015;46:85-100.
  25. Petersen JL, Mickelson JR, Valberg SJ, McCue ME. Genome-wide SNP data show little differentiation between the Appaloosa and other American stock horse breeds.. Anim Genet 2015;46:585-6.
  26. Tryon RC, Penedo MC, McCue ME, Valberg SJ, Mickelson JR, Famula TR. Evaluation of allele frequencies of inherited disease genes in subgroups of American quarter horses.. J Am Vet Med Assoc 2009;234:120-5.
  27. Valberg SJ, Geyer C, Sorum SA, Cardinet GH 3rd. Familial basis of exertional rhabdomyolysis in quarter horse-related breeds.. Am J Vet Res 1996;57:286-90.
  28. Valberg SJ, Ward TL, Rush B, Kinde H, Hiraragi H, Nahey D. Glycogen branching enzyme deficiency in quarter horse foals.. J Vet Intern Med 2001;15:572-80.
  29. Harvey JW, Calderwood Mays MB, Gropp KE, Denaro FJ. Polysaccharide storage myopathy in canine phosphofructokinase deficiency (type VII glycogen storage disease).. Vet Pathol 1990;27:1-8.
  30. Annandale EJ, Valberg SJ, Mickelson JR, Seaquist ER. Insulin sensitivity and skeletal muscle glucose transport in horses with equine polysaccharide storage myopathy.. Neuromuscul Disord 2004;14:666-74.
  31. Mariani P, Lundstrom K, Gustafsson U, Enfalt AC, Juneja RK, Andersson L. A major locus (RN) affecting muscle glycogen content is located on pig chromosome 15.. Mamm Genome 1996;7:52-4.
  32. Valberg SJ, Finno CJ, Henry ML, Schott M, Velez-Irizarry D, Peng S. Commercial genetic testing for type 2 polysaccharide storage myopathy and myofibrillar myopathy does not correspond to a histopathological diagnosis.. Equine Vet J 2021;53:690-700.
  33. Williams ZJ, Velez-Irizarry D, Petersen JL, Ochala J, Finno CJ, Valberg SJ. Candidate gene expression and coding sequence variants in Warmblood horses with myofibrillar myopathy.. Equine Vet J 2021;53:306-15.
  34. Hicks J, Wartchow E, Mierau G. Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment.. Ultrastruct Pathol 2011;35:183-96.
  35. Heller S, Worona L, Consuelo A. Nutritional therapy for glycogen storage diseases.. J Pediatr Gastroenterol Nutr 2008;47(Suppl 1):S15-21.
  36. Preisler N, Haller RG, Vissing J. Exercise in muscle glycogen storage diseases.. J Inherit Metab Dis 2015;38:551-63.
  37. Ribeiro WP, Valberg SJ, Pagan JD, Gustavsson BE. The effect of varying dietary starch and fat content on serum creatine kinase activity and substrate availability in equine polysaccharide storage myopathy.. J Vet Intern Med 2004;18:887-94.
  38. Borgia L, Valberg S, McCue M, Watts K, Pagan J. Glycaemic and insulinaemic responses to feeding hay with different non-structural carbohydrate content in control and polysaccharide storage myopathy-affected horses.. J Anim Physiol Anim Nutr (Berl) 2011;95:798-807.
  39. De La Corte FD, Valberg SJ, Mickelson JR, Hower-Moritz M. Blood glucose clearance after feeding and exercise in polysaccharide storage myopathy.. Equine Vet J 1999;31(Suppl 30):324-8.
  40. Maile CA, Hingst JR, Mahalingan KK, O'Reilly AO, Cleasby ME, Mickelson JR. A highly prevalent equine glycogen storage disease is explained by constitutive activation of a mutant glycogen synthase.. Biochim Biophys Acta Gen Subj 2017;1861:3388-98.
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.